A cancer vaccine developer has appointed a life sciences entrepreneur as chairman.
Dr. Wolfgang Oster is a managing partner for the life sciences fund at PolyTechnos, which focuses on investment in early stage, technology-oriented companies. Although the venture capital firm’s focus has been primarily on German companies, it has invested in several U.S.-based life sciences businesses. Oster worked for several years at U.S. Bioscience, which was later acquired by Maryland-based MedImmune in 1999.
Oster also serves as board member for some regional companies including Genossis, Oncoceutics and Provid.
Last month, Berwyn, Pennsylvania-based Formula Pharmaceuticals added pharmaceutical veteran Martyn Greenacre to its board and is in the midst of raising $13 million to advance its oncology therapeutic through phase 2 clinical trials.
The company’s vaccine is designed to be used during first remission for acute myeloid leukemia and other aggressive cancers.
By Stephanie Baum
Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.Visit website | More posts by Author
- Get Livefyre
- FAQ
